TetraLogic Pharmaceuticals Acquires Shape Pharmaceuticals for $13,000,000

  • Feed Type
  • Date
  • Company Name
    Shape Pharmaceuticals
  • Mailing Address
    55 Cambridge Pkwy. Cambridge, MA 02142 USA
  • Company Description
    Shape Pharmaceuticals, Inc. is developing a novel, topical HDAC inhibitor, SHP-141, currently in early clinical development, for the treatment of patients with cutaneous T cell lymphoma (CTCL).
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    TetraLogic will make a $13 million up-front cash payment for Shape, followed by undisclosed potential development and commercialization milestones, as well as tiered royalties on product sales.

Trending on Xconomy